Checking in with Cytokinetics ahead of the SEQUOIA-HCM P3 study result due in December
President and CEO Robert Blum describes aficamten's mechanism, the trial's study design, and reflects on Cytokinetics' journey of 25 years in drug development.
top of page
Follow BiotechTV
Also look for unique social pages for BiotechTV U.
.png){kind=logo}
Sponsor Spotlight
.png){kind=logo}
The NYSE is the world’s largest stock exchange, offering icons and entrepreneurs the opportunity to raise capital and change the world. Our listed companies form a powerful community committed to good governance and societal impact. Industry-leading trading technology, combined with the guidance of experienced traders creates higher market quality for NYSE-market participants
bottom of page
Comments